The information in the following tables is derived directly from each reportable segments financial reporting. Three Months Ended March 31, 2016 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 3,771,420 $  $  $ 3,771,420 International 11,260   11,260 Lymphoseek license revenue 254,050   254,050 Grant and other revenue 685,825   685,825 Total revenue 4,722,555   4,722,555 Cost of goods sold, excluding depreciation and amortization 494,639   494,639 Research and development expenses, excluding depreciation and amortization 2,417,720 241,800  2,659,520 Selling, general and administrative expenses, excluding depreciation and amortization (2) 1,012,106 (598 ) 2,975,850 3,987,358 Depreciation and amortization (3) 40,290  109,302 149,592 Loss from operations (4) 757,800 (241,202 ) (3,085,152 ) (2,568,554 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5)   (1,105,456 ) (1,105,456 ) Equity in the loss of R-NAV, LLC   (12,239 ) (12,239 ) Net loss 757,800 (241,202 ) (4,202,847 ) (3,686,249 ) Total assets, net of depreciation and amortization: United States 4,109,640 16,515 7,774,939 11,901,094 International 380,982  1,605 382,587 Capital expenditures   1,847 1,847 Three Months Ended March 31, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 1,831,022 $  $  $ 1,831,022 International 4,400   4,400 Lymphoseek license revenue 83,333   83,333 Grant and other revenue 189,701   189,701 Total revenue 2,108,456   2,108,456 Cost of goods sold, excluding depreciation and amortization 420,551   420,551 Research and development expenses, excluding depreciation and amortization 3,890,724 86,014  3,976,738 Selling, general and administrative expenses, excluding depreciation and amortization (2) 2,042,175 14,366 3,320,861 5,377,402 Depreciation and amortization (3) 33,056  116,766 149,822 Loss from operations (4) (4,278,050 ) (100,380 ) (3,437,627 ) (7,816,057 ) Other income (expense), excluding equit